Hepatocyte growth factor/scatter factor and prostate cancer: a review

Histol Histopathol. 2005 Oct;20(4):1339-49. doi: 10.14670/HH-20.1339.

Abstract

Men who die from prostate cancer do so from uncontrolled metastatic disease. A better understanding of the mechanisms involved in the progression and metastasis of prostate cancer may lead to novel therapeutic approaches to prevent its natural progression. Hepatocyte Growth Factor / Scatter factor (HGF/SF) has been demonstrated to elicit a number of key functions in numerous tissues that are important in the progression, invasion and metastasis of cancer. Studies have demonstrated that the activity of HGF/SF and its receptor c-Met are linked to disease progression in numerous cancers. However, research into these functions, which include activities as a mitogen, a motogen and an anti-apoptotic and angiogenic factor in prostate cancer are limited. This article reviews the published evidence of the roles HGF/SF plays in prostate cancer progression and highlights the clinical and therapeutic potential of research into this pleiomorphic cytokine.

Publication types

  • Review

MeSH terms

  • Animals
  • Hepatocyte Growth Factor / antagonists & inhibitors
  • Hepatocyte Growth Factor / physiology*
  • Humans
  • Male
  • Prostatic Neoplasms / metabolism*
  • Prostatic Neoplasms / pathology

Substances

  • Hepatocyte Growth Factor